PharmaSGP with significant increase in revenues and EBITDA in 2024
|
EQS-News: PharmaSGP Holding SE
/ Key word(s): Preliminary Results/Forecast
PharmaSGP with significant increase in revenues and EBITDA in 2024 Gräfelfing, April 15, 2025 – Based on preliminary, unaudited figures, the German OTC pharmaceutical company PharmaSGP Holding SE significantly increased its revenues from 2023 by 17.5% to € 118.8 million in the 2024 financial year. The sole driver of the positive business development in the past year was the organic growth of the product portfolio. Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) reached € 37.2 million in the 2024 financial year, an increase of 9.2% compared to the previous year (€ 34.1 million). The adjusted EBITDA margin amounted to 31.3% (previous year: 33.7%). Adjusted EBITDA is therefore at the upper end of the forecast range, while revenues slightly exceed the forecast for the full year 2024. "We are very satisfied with the business performance in the 2024 financial year, in which we once again achieved outstanding revenues and EBITDA figures and significantly outperformed the growth rate of the OTC pharmacy market relevant to us. The profitable growth in a challenging market environment underlines the strength of our platform strategy, enabling us to continuously drive forward the organic expansion of our portfolio and unlocking the potential of newly added products quickly, effectively and across national borders," comments Peter Gerckens, who initially joined the PharmaSGP Management Board team as Chief Commercial Officer (CCO) in July 2024 and succeeded Natalie Weigand as CEO on January 1, 2025. After more than seven years at the helm of the company, she stepped down from her position for personal reasons. CFO Michael Rudolf adds: "Driven by our high-quality products and our successful marketing strategy, our core markets in particular achieved significant revenues growth in 2024. In order to further increase our growth momentum, we will continue to launch new products on the market in the current year and explore attractive M&A opportunities for the targeted expansion of our existing brand portfolio. Thanks to our strong financial base, we have the necessary scope for this." For the current financial year 2025, the Management Board of PharmaSGP expects a further increase in revenues in a range between € 122.0 million and € 128.0 million. For adjusted EBITDA, the Management Board forecasts earnings of between € 37.0 million and € 39.0 million. This corresponds to an adjusted EBITDA margin of 28.9% to 32.0%. The forecast for the 2025 financial year takes into account, among other things, the continuing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and the potential consequences for Germany and Europe are currently unforeseeable. PharmaSGP will publish its full annual report for 2024 on April 30, 2025.
OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FIGURES
CONTACT US cometis AG
ABOUT PHARMASGP HOLDING SE PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects. The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of € 118.8 million at an adjusted EBITDA margin of 31.3% based on preliminary, unaudited figures. In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP’s product offering, increase PharmaSGP’s European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.
15.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language: | English |
| Company: | PharmaSGP Holding SE |
| Lochhamer Schlag 1 | |
| 82166 Gräfelfing | |
| Germany | |
| E-mail: | ir@pharmasgp.com |
| Internet: | https://pharmasgp.com |
| ISIN: | DE000A2P4LJ5 |
| WKN: | A2P4LJ |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Tradegate Exchange |
| EQS News ID: | 2117476 |
| End of News | EQS News Service |
|
|
2117476 15.04.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.